Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals Limited announced the cessation of Matthew Callahan as a director, effective May 23, 2025. The announcement details Callahan’s interests in the company, including a significant holding of fully paid ordinary shares and performance rights. This change in directorship may impact the company’s governance and strategic direction, influencing stakeholder confidence and market perception.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company aims to address unmet needs in skin health through innovative therapies.
Average Trading Volume: 10,516,008
Technical Sentiment Signal: Hold
Current Market Cap: A$742.5M
Find detailed analytics on BOT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue